Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT05722275
Recruiting Observational

Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics

NCT05722275 · tracked via the Priya Life Science Italy tracker
Sponsor
Chinese Academy of Sciences
Phase
Observational
Started
2023-01-01
Last updated
2023-02-14

Condition(s) studied

Gastric CancerPeritoneal Metastases

Investigational drug(s) / intervention(s)

Peritoneal metastasis status ascertainment

Peritoneal metastasis status ascertainment: Each participant with gastric cancer will undergo enhanced CT examination for detection of peritoneal metastasis. Within two weeks of CT examination, the participant will undergo diagnostic laparoscopy to confirm the status of peritoneal metastasis.

Study summary

Peritoneal metastasis of gastric cancer is difficult to be detected in time, thus delaying treatment. Based on the conventional CT images of gastric cancer, this study plans to develop, improve and validate an intelligent analysis system based on radiomics. By extracting and combining the radiomics features related to peritoneal metastasis of gastric cancer, the intelligent analysis system could predict the risk of peritoneal metastasis, and provide personalized decision suggestions for the treatment of gastric cancer.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * (1) diagnosed advanced gastric cancer (≥cT3) by endoscopy-biopsy pathology, combined with CT and/or endoscopic ultrasound; * (2) with both enhanced CT and laparoscopy; * (3) without typical peritoneal metastasis indications in CT (diffuse omental nodules or omental cake, large amount of ascites, obvious irregular thickening with high peritoneal enhancement); * (4) without other evidence of distant metastasis, and no stage IV features on CT. Exclusion Criteria: * (1) previous abdominal surgery; * (2) previous abdominal malignancies or inflammatory diseases; * (3) time intervals between CT and laparoscopy longer than 2 weeks; * (4) CT image artifacts that undermine peritoneal lesion assessment.

Primary outcome measure(s)

Trial sites (13)

FacilityCityRegionStatus
Peking University Cancer Hospital & Institute Beijing China Recruiting
Fujian Medical University Union Hospital Fuzhou China Recruiting
Affiliated Cancer Hospital and Institute of Guangzhou Medical University Guangzhou China Recruiting
Guangdong Provincial People's Hospital Guangzhou China Recruiting
Nanfang Hospital of Southern Medical University Guangzhou China Recruiting
Sun Yat-Sen University Cancer Hospital Guangzhou China Recruiting
Guizhou Provincial People's Hospital Guiyang China Recruiting
Yunnan Cancer Hospital Kunming China Recruiting
Shanxi Province Cancer Hospital Taiyuan China Recruiting
Henan Cancer Hospital Zhengzhou China Recruiting
The First Affiliated Hospital of Zhengzhou University Zhengzhou China Recruiting
Zhenjiang First People's Hospital Zhenjiang China Recruiting
Scientific Institute San Raffaele Milan Italy Recruiting

More Chinese Academy of Sciences trials in Italy

Treatment Recommendations for Gastrointestinal Cancers Via Large Language Models Recruiting
AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy Recruiting

Other trials for the same condition

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) Active, not recruiting
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination Active, not recruiting
Impact of an Omega-3 Enriched Oral Nutritional Supplement on Improving Surgical Outcomes in Patients With Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery Starting soon
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Recruiting
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05722275 on ClinicalTrials.gov ↗ ← All trials in Italy